PROVIREX is a company specialising in advanced therapy medicinal products (ATMPs). The company uses its proprietary genome editing technology to precisely remove integrated viral DNA from infected cells, thereby curing life-threatening viral infections. The focus is on therapies to cure HIV infection using a core technology based on highly specific designer recombinases. This technology is currently being tested in a Phase Ib/IIa clinical trial. In addition, platform technologies for cell-specific in vivo delivery of recombinases using AAVs or LNPs are being developed. PROVIREX has established a GMP-compliant Class S3** (Classes D-A) cleanroom, unique in Germany, which has been specifically designed for ATMP production to ensure the highest safety and quality standards. Due to the increased safety classification S3** in accordance with GenTSV in Germany, PROVIREX can expand and transduce potentially HIV-positive cells in these cleanrooms, allowing this infrastructure to be expanded for the production of CAR-T cells for people with HIV and related indications such as lymphomas.